Catalent Inc. (NYSE:CTLT) had its price objective raised by Jefferies Group from $25.00 to $28.00 in a research report sent to investors on Thursday morning, StockTargetPrices.com reports. They currently have a hold rating on the stock.
A number of other research analysts have also recently commented on CTLT. Wells Fargo & Co. raised shares of Catalent from a market perform rating to an outperform rating in a research report on Tuesday, June 21st. Bank of America Corp. raised shares of Catalent from a neutral rating to a buy rating in a report on Monday, June 20th. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company. Catalent has a consensus rating of Hold and a consensus target price of $27.83.
Shares of Catalent (NYSE:CTLT) opened at 25.83 on Thursday. The stock has a 50 day moving average of $25.26 and a 200 day moving average of $25.67. The stock has a market cap of $3.22 billion, a P/E ratio of 29.02 and a beta of 1.41. Catalent has a one year low of $18.92 and a one year high of $32.24.
Hedge funds have recently modified their holdings of the company. M&T Bank Corp acquired a new stake in shares of Catalent during the first quarter worth $207,000. Forward Management LLC boosted its stake in shares of Catalent by 8.7% in the first quarter. Forward Management LLC now owns 17,656 shares of the company’s stock worth $471,000 after buying an additional 1,411 shares during the period. Royal Bank of Canada boosted its stake in shares of Catalent by 81.5% in the first quarter. Royal Bank of Canada now owns 34,988 shares of the company’s stock worth $933,000 after buying an additional 15,706 shares during the period. Envestnet Asset Management Inc. boosted its stake in shares of Catalent by 45.2% in the first quarter. Envestnet Asset Management Inc. now owns 38,974 shares of the company’s stock worth $1,039,000 after buying an additional 12,141 shares during the period. Finally, UBS Group AG boosted its stake in shares of Catalent by 1.1% in the first quarter. UBS Group AG now owns 66,308 shares of the company’s stock worth $1,769,000 after buying an additional 712 shares during the period. 99.72% of the stock is currently owned by institutional investors.
Catalent Company Profile
Catalent, Inc is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Company’s segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecule’s lifecycle.
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.